DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
about
Wnt signaling pathway in non-small cell lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesObesity, inflammation, and lung injury (OILI): the good.Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma.Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancerDNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.An exceptional case of myelodysplastic syndrome with myelofibrosis following combination chemotherapy for squamous cell lung cancerWif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation.Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.Wnt signaling as potential therapeutic target in lung cancer.Pharmacoepigenetics: an element of personalized therapy?
P2860
Q26825936-C57F5E53-2E96-4467-9712-55CFED855F0FQ27014117-08934A0B-DFAA-452C-BB23-241069B86EC0Q30363313-E1F3151C-AC22-4EA1-82D5-326262E92590Q33739448-1A715AE0-CC50-42A0-B22D-3046A72E91DBQ33829495-7E429351-BDEF-4984-BCC7-9E6072483160Q34249360-077DD84C-D7F9-4FB3-9D55-A95AB058F6A3Q34544542-8E9BA2C5-BD0F-46E4-BD60-3B426E3772ADQ35176964-9B8DF839-8C1E-4F15-A388-38F1DA87AF90Q37034820-0604E13C-8E29-4E92-BB76-B8A41F0F1783Q37462417-EBA8DA5F-E217-4920-8BE8-62307CB36BB0Q37596771-127A70F1-2626-4BB6-93B0-FEF8013DBBFDQ38735754-295C56D5-309D-4488-8320-B0EB9D18F644Q39012550-F987E762-E6CE-4FE9-8D1D-A088AC6CEC3E
P2860
DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@ast
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@en
type
label
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@ast
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@en
prefLabel
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@ast
DNA Methylation status of Wnt ...... in non-small cell lung cancer.
@en
P2093
P2860
P50
P356
P1476
DNA Methylation status of Wnt ...... in non-small cell lung cancer
@en
P2093
Jianchun Duan
Shuhang Wang
Tongtong An
Yuyan Wang
P2860
P2888
P356
10.1186/1756-9966-31-80
P577
2012-09-25T00:00:00Z
P5875
P6179
1041391254